摘要
制备PARP抑制剂奥拉帕利晶型A.以2-氟-5-[(4-氧代-3,4-二氢酞嗪-1-基)甲基]苯甲酸为原料,与N-叔丁氧羰基哌嗪缩合为酰胺,脱去叔丁氧羰基保护,再与环丙基甲酸缩合,经三步反应制得奥拉帕利粗品.粗品经乙醇水溶液处理获得晶型A.目标产物的化学结构被1H-NMR,^(13)C-NMR,MS和元素分析确证,晶型经XRPD,DSC,TGA表征,总收率为51%.优化后的合成路线反应条件温和,操作简便,对环境友好,适宜工业化生产.
The paper is to prepare crystal form A of PARP inhibitor Olaparib.The crude Olaparib was prepared from 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid by amidation with N-tert-butyloxycarbonylpiperazine,removing the protected N-boc group,and then condensation with cyclopropyl acid.Finally,the crude was treated with aqueous ethanol to produce crystal form A,which overall yield was 51%.The chemical structure of the target molecule was confirmed by 1H-NMR,^(13)C-NMR,MS and elemental analysis,and the crystal form was characterized by XRPD,DSC,TGA.In conclusion,the optimized synthetic route has the advantages of mild reaction conditions,operation easiness,environmental friendliness,and is suitable for industrial production.
作者
李宏名
胡瑞馨
张祥阳
郑维江
张娇
LI Hongming;HU Ruixin;ZHANG Xiangyang;ZHENG Weijiang;ZHANG Jiao(Xinxiang Medical University,Xinxiang 453003,China;College of Horticulture,Sichuan Agricultural University,Chengdu 611130,China;Sinopharm Chuankang Pharmaceutical Co.,Ltd,Chengdu 611731,China;Sichuan Kelun Pharmaceutical Research Institute Co.,Ltd,Chengdu 611138,China)
出处
《牡丹江师范学院学报(自然科学版)》
2022年第4期45-49,共5页
Journal of Mudanjiang Normal University:Natural Sciences Edition
基金
国家“重大新药创制”科技重大专项资助项目(2012ZX092021-013)
成都市高新区重点科技创新计划资助项目(15DFZD023)。